Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 14/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| [Leu5]Enkephalin SCHEMBL29687098 | 1.00 | OPRD1 (0.67) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL631958 | 0.93 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL11399380 | 0.93 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL631959 | 0.93 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL30857 | 0.93 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL16189980 | 0.93 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL25236888 | 0.93 | OPRD1 (0.73) | OPRD1OPRM1OPRK1 | |
| Enkephalin SCHEMBL30400052 | 0.93 | OPRD1 (0.73) | OPRD1OPRM1OPRK1 | |
| SCHEMBL14241976 | 0.92 | OPRD1 (0.65) | OPRD1OPRM1OPRK1 | |
| SCHEMBL12962865 | 0.92 | OPRD1 (0.65) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189383-A1 | Application of Inhibitors Targeting CD226 Molecules in Anti-Tumor Metastasis | AIR FORCE MEDICAL UNIVERSITY (CN) | 2024-06-13 | — | — | US | claimed |
| US-20240052418-A1 | METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-02-15 | — | — | US | claimed |
| US-11814681-B2 | Method for predicting a subjects response to SLC modulator therapy | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-14 | — | — | US | claimed |
| WO-2023179802-A1 | APPLICATION OF INHIBITOR TARGETING CD226 MOLECULE IN ANTI-TUMOR METASTASIS | 中国人民解放军空军军医大学 | 2023-09-28 | — | — | WO | claimed |
| EP-3773730-B1 | DRUG DELIVERY FORMULATIONS | UNIV CALIFORNIA (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4731637-A1 | METHODS OF CHEMICAL SYNTHESIS OF PEPTIDES | Imperial College Innovations Limited (GB) | 2026-04-29 | — | — | EP | disclosed |
| US-12564579-B2 | Topical formulations of (1S)-1-phenyl-2-pyridin-2-ylethanamine | BIOHAVEN THERAPEUTICS LTD. (VG) | 2026-03-03 | — | — | US | disclosed |
| US-20250312463-A1 | AUGMENTED PEPTIDE COMPOSITIONS AND METHODS | Neo7Bioscience, Inc. (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250195441-A1 | GASTRORETENTIVE FORMULATIONS CONTAINING PROTEIN OR PEPTIDE | APET Holding B.V. (NL) | 2025-06-19 | — | — | US | disclosed |
| US-20250115940-A1 | CELL CULTURE PROCESS | JANSSEN BIOTECH, INC. | 2025-04-10 | — | — | US | disclosed |
| EP-4486301-A1 | GASTRORETENTIVE FORMULATIONS CONTAINING PROTEIN OR PEPTIDE | APeT Holding B.V. (NL) | 2025-01-08 | — | — | EP | disclosed |
| CN-114126615-B | Opioid receptor antagonist prodrugs | 尼萨姆实验室公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20230190719-A1 | TOPICAL FORMULATIONS OF (1S)-1-PHENYL-2-PYRIDIN-2-YLETHANAMINE | BIOHAVEN THERAPEUTICS LTD (US) | 2023-06-22 | — | — | US | disclosed |
| EP-4168116-A1 | TOPICAL FORMULATIONS OF (1S)-1-PHENYL-2-PYRIDIN-2-YLETHANAMINE | Biohaven Therapeutics Ltd. (US) | 2023-04-26 | — | — | EP | disclosed |
| WO-2023279211-A1 | METAL-CONTAINING POLYMERS FOR MASS CYTOMETRY | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2023-01-12 | — | — | WO | disclosed |
| US-20220249365-A1 | BIOERODIBLE IMPLANT FOR LONG-TERM DRUG DELIVERY AND ASSOCIATED METHODS OF MANUFACTURE AND USE | Gesea Biosciences Inc. (US) | 2022-08-11 | — | — | US | disclosed |
| EP-2695618-B2 | Pharmaceutical composition comprising lacosamide and levetiracetam for use in the treatment of epilepsy | UCB PHARMA GMBH (DE) | 2022-05-11 | — | — | EP | disclosed |
| EP-3965765-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | Nirsum Laboratories, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| US-10297435-B2 | Micro-nozzle array | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2019-05-21 | — | — | US | disclosed |
| US-20160217994-A1 | Micro-Nozzle Array | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564579-B2 | Topical formulations of (1S)-1-phenyl-2-pyridin-2-ylethanamine | CERS2, CNR2, FAAH2 | OPRD1 696/4885OPRM1 507/4885OPRK1 1115/4885 |
| US-20230190719-A1 | TOPICAL FORMULATIONS OF (1S)-1-PHENYL-2-PYRIDIN-2-YLETHANAMINE | TRPV1, PNN, SLC18A2 | OPRD1 51/4885OPRM1 99/4885OPRK1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.